Global Health Q2 FY27 Share Price & Earnings Call Analysis
Part of: Nifty Midcap 150 · NIFTY LargeMidcap 250 · Nifty MidSmallcap 400 · Nifty 500 · Nifty Total Market
- Market cap
- ₹38,381 Cr
- P/E
- 59.28
- ROE
- 15.17%
- PEG
- 3.04
- Price to sales
- 7.60
- Debt to equity
- 0.31
- 52W high / low
- ₹1,509 / ₹961
- Sales growth (5Y)
- 24.97%
- EBITDA margin
- 22.12%
- Net profit margin
- 12.58%
- Promoter holding
- 33.00%
- Sales (last year)
- ₹5,053 Cr
Global Health Limited is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India. The company has key specialties in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology.[1]
Guidance scorecard · Q2 FY27 call
What Global Health's management guided
and where it ranks in Healthcare Services
Healthcare Services
RevenueQ2 FY27 call
20–40%- Strong growth trajectory with 34% YoY increase in consolidated revenue from operations in Q2 FY27.
- Inpatient volumes grew 30% YoY; outpatient volumes increased 38% YoY, indicating sustained demand.
- Capacity expansion includes adding approx. 3,450 beds over next few years, nearly doubling network capacity to 7,600 beds.
- Planned capital expenditure of over INR 6,000 crores in next 4-5 years for new hospitals, capacity expansion, and infrastructure.
- Cluster 2 hospitals (developing units) show robust volume growth, e.g., 26% inpatient volume increase ex-Noida.
- Growth driven by volume rather than tariff hikes; ARPP stable with nominal increases (~5% or less).
- Expansion into new regions like Ghaziabad with planned 500-bed facility to tap emerging markets.
2 more points from Global Health's call on revenue
Create a free account to keep reading this call
MarginsQ2 FY27 call
FlatSee what Global Health said on margins — free account, 30 seconds.
CapexQ2 FY27 call
Planned- Medanta has a significant bed addition pipeline expected to add approximately 3,450 beds over the next few years, nearly doubling network capacity to over 7,600 beds.
- Planned capital expenditure is over INR 6,000 crores over the next 4 to 5 years, covering upcoming hospitals, capacity expansion at existing facilities, and supporting infrastructure.
- New greenfield hospitals include a 500-bed multi-specialty hospital in Ghaziabad, among 6 new greenfield hospitals in the expansion pipeline.
- Construction progress: South Delhi (GK) progressing well; Mumbai and Guwahati have approvals and active construction; Varanasi drawings submitted for approval.
2 more points from Global Health's call on capex
Create a free account to keep reading this call
FundraisingQ2 FY27 call
See what Global Health said on fundraising — free account, 30 seconds.
Order bookQ2 FY27 call
- Expansion pipeline includes 6 new greenfield hospitals aimed at doubling bed capacity over time.
- Ongoing projects: South Delhi (GK), Mumbai, Guwahati, Varanasi, Pitampura (delayed due to revised approvals), and a recently acquired 2.61-acre land parcel in Ghaziabad for a 500-bed multi-specialty hospital.
- Construction has started or is progressing on most sites, with some temporary slowdowns (e.g., monsoon in Guwahati, pollution norms in South Delhi).
2 more points from Global Health's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM QualityGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Healthcare Services companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹867 Cr | — | |
| 2 | 40%+ | Flat | ₹574 Cr | 21.8 | |
| 3 | Aster DM Quality | 20–40% | Up 2%+ | ₹65,342 Cr | 124.7 |
| 4 | 20–40% | Up 2%+ | ₹14,999 Cr | 35.2 | |
| 5 | 20–40% | Up 2%+ | ₹1,579 Cr | 15.6 | |
| 6 | 20–40% | Up 2%+ | ₹587 Cr | 19.7 |
Sign up free to see every company in the sector ranking and track Global Health.
Pro shows every company guiding 40%+ revenue growth →Full Healthcare Services rankingGlobal Health announcements
All announcements →- Capex / expansionNotableGlobal Health (Medanta) Q2 FY27 revenue up 33.6%; 500-bed Ghaziabad hospital approved
- Dividend / buyback / bonusNotableGlobal Health Ltd announces Q1 FY 2026-27 financial results and management changes
- Capex / expansionNotableGlobal Health Ltd Q1 results; Chief Digital Officer named; Guwahati beds to 650
- Capex / expansionNotableGlobal Health Limited announces Q1 FY 2026-27 financial results and new appointment
- Dividend / buyback / bonusNotableGlobal Health Limited reports Q1 FY27 results and appoints Chief Digital Officer
Financials of Global Health
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Global Health
Shareholding breakup across reporting periods.
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters + | 33.05% | 33.04% | 33.04% | 33.04% | 33.03% | 33.03% | 33.01% | 33.01% | 33.01% | 33.01% | 33.00% | 33.00% |
| FIIs + | 11.36% | 12.10% | 12.94% | 12.21% | 12.48% | 11.76% | 11.54% | 11.41% | 10.54% | 10.15% | 9.46% | 9.92% |
| DIIs + | 11.15% | 10.25% | 10.57% | 11.11% | 10.51% | 11.93% | 12.20% | 12.97% | 13.99% | 14.76% | 16.89% | 17.01% |
| Public + | 44.45% | 44.60% | 43.44% | 43.64% | 43.98% | 43.28% | 43.19% | 42.56% | 42.41% | 42.01% | 40.55% | 39.96% |
| Others + | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.06% | 0.06% | 0.06% | 0.08% | 0.09% | 0.12% |
| No. of Shareholders | 1,24,775 | 1,66,253 | 1,55,307 | 1,49,722 | 1,48,633 | 1,54,688 | 1,56,372 | 1,55,806 | 1,51,241 | 1,47,390 | 1,40,531 | 1,35,371 |
Financials of Global Health
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 844 | 836 | 809 | 861 | 957 | 943 | 931 | 1,031 | 1,099 | 1,121 | 1,159 | 1,304 | 1,469 |
| YoY Sales growth | +24% | +20% | +14% | +10% | +13% | +13% | +15% | +20% | +15% | +19% | +24% | +26% | +34% |
| Expenses + | 631 | 620 | 629 | 675 | 728 | 706 | 707 | 784 | 868 | 904 | 915 | 1,017 | 1,099 |
| Operating Profit | 213 | 216 | 179 | 186 | 228 | 238 | 225 | 247 | 231 | 217 | 244 | 287 | 370 |
| OPM % | 25% | 26% | 22% | 22% | 24% | 25% | 24% | 24% | 21% | 19% | 21% | 22% | 25% |
| Other Income + | 21 | 18 | 27 | 22 | 18 | 16 | -27 | 20 | 36 | -15 | 37 | 22 | 24 |
| Interest | 20 | 18 | 18 | 18 | 16 | 16 | 15 | 14 | 17 | 22 | 27 | 27 | 28 |
| Depreciation | 43 | 44 | 45 | 47 | 49 | 48 | 49 | 45 | 50 | 61 | 67 | 69 | 71 |
| Profit before tax | 171 | 172 | 143 | 144 | 181 | 189 | 133 | 208 | 200 | 120 | 187 | 213 | 295 |
| Tax % | 27% | 28% | 11% | 26% | 28% | 24% | 24% | 24% | 21% | 21% | 24% | 26% | 26% |
| Net Profit + | 125 | 124 | 127 | 106 | 131 | 143 | 101 | 159 | 158 | 95 | 142 | 157 | 219 |
| EPS in Rs | 4.66 | 4.61 | 4.74 | 3.96 | 4.87 | 5.32 | 3.78 | 5.92 | 5.89 | 3.54 | 5.36 | 5.90 | 8.21 |
Financials of Global Health
Profit & Loss
Annual income statement trend
| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,382 | 1,343 | 1,456 | 1,500 | 1,447 | 2,167 | 2,710 | 3,275 | 3,692 | 4,410 | 5,053 |
| Sales growth | +8% | +3% | -4% | +50% | +25% | +21% | +13% | +19% | +26% | ||
| Expenses + | 1,081 | 1,218 | 1,283 | 1,309 | 1,250 | 1,709 | 2,073 | 2,466 | 2,806 | 3,480 | 3,935 |
| Operating Profit | 301 | 125 | 172 | 192 | 197 | 458 | 637 | 809 | 886 | 930 | 1,118 |
| OPM % | 22% | 9% | 12% | 13% | 14% | 21% | 24% | 25% | 24% | 21% | 22% |
| Other Income + | 45 | 49 | 50 | 44 | 31 | 39 | 49 | 75 | 29 | 98 | 68 |
| Interest | 14 | 28 | 38 | 57 | 73 | 86 | 86 | 84 | 74 | 90 | 103 |
| Depreciation | 70 | 86 | 102 | 115 | 123 | 130 | 150 | 173 | 194 | 223 | 267 |
| Profit before tax | 262 | 60 | 83 | 64 | 32 | 281 | 449 | 627 | 647 | 715 | 815 |
| Tax % | 35% | 45% | 38% | 43% | 11% | 30% | 27% | 24% | 26% | 23% | |
| Net Profit + | 170 | 33 | 51 | 36 | 29 | 196 | 326 | 478 | 481 | 554 | 613 |
| EPS in Rs | 7.02 | 1.36 | 2.09 | 1.47 | 1.16 | 7.75 | 12.16 | 17.81 | 17.92 | 20.70 | 23.01 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 2% |
Financials of Global Health
Balance Sheet
Capital structure and asset base
| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 48 | 48 | 49 | 49 | 50 | 51 | 54 | 54 | 54 | 54 | 54 |
| Reserves | 976 | 1,136 | 1,246 | 1,300 | 1,333 | 1,565 | 2,375 | 2,852 | 3,333 | 3,908 | 4,270 |
| Borrowings + | 165 | 456 | 787 | 929 | 931 | 1,109 | 1,122 | 802 | 718 | 1,190 | 1,353 |
| Other Liabilities + | 295 | 343 | 347 | 388 | 380 | 421 | 547 | 572 | 662 | 753 | 930 |
| Total Liabilities | 1,485 | 1,984 | 2,430 | 2,666 | 2,694 | 3,146 | 4,097 | 4,280 | 4,766 | 5,905 | 6,606 |
| Fixed Assets + | 914 | 1,094 | 1,194 | 1,703 | 1,616 | 1,776 | 2,050 | 2,236 | 2,514 | 3,795 | 3,957 |
| CWIP | 12 | 317 | 666 | 382 | 464 | 439 | 327 | 388 | 533 | 132 | 207 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 3 |
| Other Assets + | 559 | 573 | 570 | 581 | 615 | 930 | 1,720 | 1,656 | 1,716 | 1,975 | 2,440 |
| Total Assets | 1,485 | 1,984 | 2,430 | 2,666 | 2,694 | 3,146 | 4,097 | 4,280 | 4,766 | 5,905 | 6,606 |
Financials of Global Health
Cash Flows
Operating, investing and financing cash movement
| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 228 | 63 | 166 | 175 | 242 | 311 | 645 | 612 | 624 | 714 |
| Cash from Investing Activity + | -241 | -69 | -249 | -87 | -239 | -421 | -342 | -441 | -721 | -1,089 |
| Cash from Financing Activity + | -7 | 9 | 97 | -1 | -81 | 160 | 346 | -514 | -97 | 272 |
| Net Cash Flow | -20 | 3 | 14 | 87 | -78 | 50 | 648 | -343 | -194 | -103 |
| Free Cash Flow | 71 | -81 | -133 | -13 | 100 | 38 | 409 | 335 | 110 | -123 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 108% | 93% | 135% | 121% | 131% | 89% | 118% | 98% | 89% | 90% |
Financials of Global Health
Ratios
Working capital efficiency and return ratios
| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 20 | 41 | 41 | 36 | 34 | 30 | 26 | 24 | 29 | 34 |
| Inventory Days | 28 | 26 | 26 | 43 | 42 | 36 | 35 | 32 | 28 | 29 |
| Days Payable | 92 | 124 | 142 | 147 | 138 | 90 | 114 | 90 | 81 | 89 |
| Cash Conversion Cycle | -45 | -56 | -75 | -67 | -62 | -24 | -52 | -34 | -24 | -26 |
| Working Capital Days | -23 | -33 | -18 | -31 | -48 | -20 | -37 | -32 | -21 | -7 |
| ROCE % | 6% | 6% | 5% | 15% | 17% | 20% | 20% | 17% |
Guidance history
How Global Health's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q2 FY27 call → | 20–40% | Flat | Planned | — | — |
| Q1 FY27 call → | 20–40% | Flat | Planned | Planned | Rising |
| Q4 FY26 call → | 20–40% | Flat | Planned | — | Rising |
| Q3 FY26 call → | 10–20% | Flat | Planned | — | Rising |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
66 out of 100 — Steady
Over the past year its share price has moved roughly in the middle of the stocks we track.
| Period | Share price change | Better than … of 1,928 stocks |
|---|---|---|
| Last 12 months | +14.0% | 67% |
| Last 6 months | +15.2% | 71% |
| Last 3 months | −3.3% | 55% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,928 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Global Health: 0.4 × 67 + 0.4 × 71 + 0.2 × 55 = 66.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 9 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Global Health's management said in earlier quarters
Others in Healthcare Services this season
- Nidan Laboratories & Healthcare (Q2 FY27)
Operating Margin: Not explicitly stated as a percentage; however, total income from operations is Rs 1,201.76 lakhs, so approximate operating margin = (EBITDA…
- Suven Life Sciences (Q2 FY27)
91.92 lakhs for the quarter ended September 30, 2025, indicating a revenue increase of approximately 30.3%. Key results statement takeaways from Suven Life Scie
- Aster DM Quality (Q2 FY27)
Q2 FY27 revenue: INR 2,829 Cr, up 19% YoY from INR 2,382 Cr in Q2 FY26 (Page 6, 9, 10). Key investor presentation takeaways from Aster DM Quality Care Ltd's Q2
- Fortis Healthcare (Q2 FY27)
Patient volume in diagnostics grew 5.8% YoY in Q2 and 9.9% quarter-on-quarter, with test volume growth at 7.2% YoY. Key concall takeaways from Fortis…
